Testing AR1005 for Lewy body dementia
Part of Brain & nervous system, Mental health clinical trials.
This trial tests an experimental oral medication called AR1005 for people with Lewy body dementia or its early stage. It aims to see if the drug is safe and helps with memory, thinking, and daily function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 years or older.
- You have been diagnosed with dementia with Lewy bodies or mild cognitive impairment likely due to Lewy bodies.
- You can speak and understand Korean.
- You have a caregiver who can help you during the trial.
- You can walk on your own or with a walker, cane, or wheelchair.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a non-invasive ultrasound treatment to the head can improve symptoms in people with mild Lewy body dementia. You may be asked to complete memory and thinking tests and follow-up visits to see if symptoms change.
This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease (mild cognitive impairment or mild dementia). The goal is to see if it is safe and slows down memory decline.
This study looks at how brain changes affect attention and thinking in people with Lewy body dementia. It includes brain scans, an EEG, and a medication option to see if it helps with symptoms.
This early-stage study tests whether ambroxol can act as a “disease-modifying” treatment for Lewy body dementia, meaning it aims to change how the illness progresses rather than only relieve symptoms. You may be asked to complete brain testing and have stable medications while the study monitors memory, thinking, and safety.
This trial tests a new drug called ACP-204 for people with dementia from Lewy body disease or Parkinson's who also have hallucinations or delusions. The goal is to see if the drug can safely reduce these symptoms without worsening thinking problems.
This trial tests whether ambroxol (a mouth medicine) can help people with new or early dementia with Lewy bodies (DLB) or mild cognitive impairment linked to DLB. Participants take the medicine for about 18 months while the study tracks safety and changes over time.
Hear when a new Lewy Body Dementia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.